4 items across 4 digests
CVS will restore Zepbound coverage on October 1 and add Eli Lilly's newly approved Foundayo obesity pill to drug plans starting June 1. This expanded coverage could significantly increase market access for weight management medications.
Eli Lilly raised its full-year sales outlook by $2 billion driven by skyrocketing sales of diabetes/weight-loss drugs Zepbound and Mounjaro. This massive revenue increase demonstrates the commercial success of GLP-1 medications, positioning Lilly to capture significant market share in the growing obesity treatment sector.
Novartis, Amgen and Eli Lilly are developing drugs targeting a specific form of cholesterol to create the next blockbuster cardiology treatments. This represents a major pharmaceutical investment shift toward precision cardiovascular medicine that could reshape the $50+ billion heart disease drug market.
The FDA approved Eli Lilly's GLP-1 pill Foundayo, entering the oral weight loss drug market three months after Novo Nordisk's oral Wegovy launch. This creates competition in the rapidly growing weight loss pharmaceutical market.
DailySand